Sign in or create a free account to view this dataset's chart and data table.
Key Takeaway
- Endocrine system medicines achieved a CAGR of 6% between FY 2019–20 and FY 2024–25. The category includes corticosteroids, sex hormones, anabolic steroids, pituitary hormones and insulin preparations. The growth rate reflects a positive sales trajectory across the reporting period.
About This Dataset
Annual sales data for animal health endocrine system medicines, including anabolic steroids, corticosteroids and adrenal compounds, sex hormones, pituitary tropic hormones and insulin preparations. These products support the management of hormonal, metabolic and related physiological conditions in animals. The dataset tracks aggregated sales by financial year from 1 July to 30 June.
Methodology
Sign in or create a free account to view this dataset's methodology and sources.
Available formats: Excel, CSV, PNG, PDF.
Transform Data Into Better Business Decisions
Join organizations that rely on statSCALAR for trusted market intelligence, industry statistics, commodity insights and enterprise research.